Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ISRNASDAQ:NMRDNASDAQ:NVNONASDAQ:PLSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeISRIsoray$0.37$0.19▼$0.45$54.57M1.48290,697 shs145,000 shsNMRDNemaura Medical$0.07$0.08$0.06▼$1.25$2.91M-0.0613,025 shs42,662 shsNVNOenVVeno Medical$5.50+12.0%$5.54$2.51▼$6.97$65.39M1.1760,177 shs139,226 shsPLSEPulse Biosciences$6.86+0.1%$8.84$3.78▼$13.62$378.29M1.67189,624 shs123,848 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceISRIsoray0.00%0.00%0.00%0.00%0.00%NMRDNemaura Medical0.00%-2.83%-15.11%-20.00%-90.96%NVNOenVVeno Medical+12.02%+15.55%-2.65%+31.26%+39.06%PLSEPulse Biosciences+0.15%-11.83%-23.44%-21.15%+19.30%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationISRIsorayN/AN/AN/AN/AN/AN/AN/AN/ANMRDNemaura Medical1.7683 of 5 stars3.50.00.04.50.61.70.0NVNOenVVeno Medical0.057 of 5 stars0.02.00.00.00.01.70.6PLSEPulse BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceISRIsorayN/AN/AN/AN/ANMRDNemaura Medical3.00Buy$2.503,372.22% UpsideNVNOenVVeno MedicalN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookISRIsoray$10.80M0.00N/AN/A$0.43 per share0.00NMRDNemaura Medical$80K36.32N/AN/A($0.41) per share-0.18NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/APLSEPulse Biosciences$700K541.16N/AN/A$0.81 per share8.47Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateISRIsoray-$7.27M-$0.07N/AN/AN/A-115.91%-17.12%-16.15%N/ANMRDNemaura Medical-$14.14M-$0.39N/A∞N/AN/AN/A-142.69%N/ANVNOenVVeno Medical-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%5/6/2024 (Estimated)PLSEPulse Biosciences-$42.21M-$0.89N/A∞N/AN/A-112.74%-61.09%5/9/2024 (Estimated)Latest PLSE, NVNO, NMRD, and ISR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PLSEPulse BiosciencesN/A-$0.21-$0.21-$0.20N/AN/A2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/A2/12/2024Q3 2024NMRDNemaura MedicalN/A-$0.12-$0.12-$0.17N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthISRIsorayN/AN/AN/AN/AN/ANMRDNemaura MedicalN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioISRIsorayN/A14.3813.99NMRDNemaura MedicalN/A0.190.03NVNOenVVeno MedicalN/A34.2234.23PLSEPulse BiosciencesN/A6.766.76OwnershipInstitutional OwnershipCompanyInstitutional OwnershipISRIsoray11.32%NMRDNemaura Medical4.41%NVNOenVVeno Medical34.71%PLSEPulse Biosciences76.95%Insider OwnershipCompanyInsider OwnershipISRIsoray2.42%NMRDNemaura Medical41.60%NVNOenVVeno Medical17.00%PLSEPulse Biosciences69.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableISRIsorayN/A142.11 million138.67 millionNot OptionableNMRDNemaura Medical3640.35 million23.57 millionOptionableNVNOenVVeno Medical1913.32 million11.05 millionOptionablePLSEPulse Biosciences6155.22 million16.73 millionOptionablePLSE, NVNO, NMRD, and ISR HeadlinesSourceHeadlinePulse Biosciences to raise $60Mmassdevice.com - March 29 at 10:48 AMQ4 2023 Pulse Biosciences Inc Earnings Callfinance.yahoo.com - March 29 at 10:48 AMPLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023investorplace.com - March 28 at 11:31 PMPulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023finance.yahoo.com - March 28 at 7:45 PMPulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Resultsbusinesswire.com - March 28 at 4:12 PMPulse Biosciences Announces Plans to Initiate a Rights Offeringbusinesswire.com - March 28 at 4:10 PMPLSE Apr 2024 25.000 callfinance.yahoo.com - March 17 at 10:01 AMPLSE Oct 2024 17.500 callfinance.yahoo.com - March 17 at 12:13 AMPLSE Oct 2024 12.500 callfinance.yahoo.com - March 16 at 2:13 PMPLSE Jul 2024 2.500 putfinance.yahoo.com - March 16 at 2:13 PMPulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024businesswire.com - March 14 at 4:05 PMPulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearancemsn.com - March 13 at 7:07 PMFDA clears pulsed field ablation electrode tech from Pulse Biosciencesmassdevice.com - March 11 at 1:28 PMWhat to know about low blood pressure with a high pulsemedicalnewstoday.com - March 10 at 2:46 PMFDA clears Pulse Biosciences' soft tissue ablation systeminvesting.com - March 10 at 2:46 PMPulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode Systemmarkets.businessinsider.com - March 9 at 1:21 AMPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode Systemstockhouse.com - March 8 at 3:19 PMPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode Systembusinesswire.com - March 8 at 1:17 PMPulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablationmassdevice.com - February 14 at 12:51 PMPulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Upmarkets.businessinsider.com - February 14 at 12:51 PMPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Studyfinance.yahoo.com - February 14 at 12:51 PMPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Studybusinesswire.com - February 14 at 8:00 AMCompanies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growthfinance.yahoo.com - February 2 at 12:21 PMPulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposiumfinance.yahoo.com - January 31 at 12:57 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIsorayNYSE:ISRIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Nemaura MedicalNASDAQ:NMRDNemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Pulse BiosciencesNASDAQ:PLSEPulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.